1,7-dioxahexahydroindan | 92944-64-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡喃类
• 英文名称: 1,7-dioxahexahydroindan
• 英文别名: Hexahydro-furo[2,3-b]pyran；3,3a,4,5,6,7a-hexahydro-2H-furo[2,3-b]pyran
• CAS: 92944-64-4
• 化学式: C₇H₁₂O₂
• 分子量: 128.171
• InChiKey: RWLBEFHBHIUHSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,7-dioxahexahydroindan 在 盐酸 作用下， 生成 (+/-)-3-hydroxymethyl-hexane-1,6-diol
  参考文献：
  名称：

  Paul; Tchelitcheff, Bulletin de la Societe Chimique de France, 1954, p. 672,674

  摘要：

  DOI：
• 作为产物：
  描述：

  1,7-dioxa-4,7,8,9-tetrahydroindan 在 Pd on polyacrylic acid 氢气 作用下， 以 乙醇 为溶剂， 以100%的产率得到1,7-dioxahexahydroindan
  参考文献：
  名称：

  使用含聚合物的催化剂氢化杂环化合物

  摘要：

  DOI：

  10.1007/bf00513563

文献信息

• KARAXANOV, EH. A.;LOKTEV, A. S.;PSHEZHETSKIJ, V. S.;STEPANOVA, I. P.;DEDO+, XIMIYA GETEROTSIKL. SOEDIN., 1984, N 8, 1032-1034
  作者：KARAXANOV, EH. A.、LOKTEV, A. S.、PSHEZHETSKIJ, V. S.、STEPANOVA, I. P.、DEDO+

  DOI：——

  日期：——
• [EN] NOVEL BIFUNCTIONAL METNASE/INTNASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS OF TREATMENT OF CANCER<br/>[FR] NOUVEAUX INHIBITEURS BIFONCTIONNELS DE METNASE/INTNASE ET COMPOSITIONS APPARENTÉES ET PROCÉDÉS DE TRAITEMENT DU CANCER
  申请人：STC UNM

  公开号：WO2011094260A2

  公开（公告）日：2011-08-04

  This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical bifunctional inhibitors of DNA replication and repair proteins Metnase and/or Intnase (also termed Gypsy Integrase, Gypsy Integrease-1, Gypsy Retransposon Integrase 1, or GIN-I) that simultaneously damage DNA, and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols, including radiation therapy. In preferred embodiments, compounds, compositions and methods of treatment of the invention are used to treat a patient suffering from leukemia (e.g. acute myeloid leukemia (AML) and related cancers. In certain aspects of such treatments, compounds, compositions and methods of treatment of the invention are administered as a monotherapy (in some cases, to patients who have exhibited resistance to Topo IIalpha inhibitors such as VP- 16), or are co-administered with a Topo IIalpha inhibitor or other anti-cancer agents as otherwise described herein or in combination with radiation therapy.
• Hydrogenation of heterocyclic compounds using polymer-containing catalysts
  作者：�. A. Karakhanov、A. S. Loktev、V. S. Pshezhetskii、I. P. Stepanova、A. G. Dedov

  DOI：10.1007/bf00513563

  日期：1984.8
• Paul; Tchelitcheff, Bulletin de la Societe Chimique de France, 1954, p. 672,674
  作者：Paul、Tchelitcheff

  DOI：——

  日期：——